Low Dose Naltrexone
A powerful tool to increase energy, maximize endogenous endorphins, and minimize inflammation.
Table of contents
As longevity science uncovers surprising connections between seemingly unrelated drugs and health outcomes, the curious case of Low-Dose Naltrexone (LDN) has captured researchers' attention. Originally designed as a treatment for addiction, LDN's impact on our biological systems has revealed unexpected benefits in modulating the immune response and fighting chronic inflammatory diseases. Through subtle increases in endorphin production and a cascade of anti-inflammatory responses, LDN presents an intriguing opportunity for enhancing overall well-being. In this article, we explore the multifaceted potential of LDN in extending healthspan, delve deeper into its proposed mechanisms of action, and examine its therapeutic applications in conditions like Multiple Sclerosis, Fibromyalgia, and Inflammatory Bowel Disease (IBD)—highlighting an unlikely candidate turned powerful ally in the pursuit of longevity and health.
By: Daniel Tawfik
Many of the longevity compounds we study have been available for decades to treat conditions unrelated to longevity. Through observational studies, though, we can observe how patients with an assortment of health conditions unrelated to the primary use of the medication have ancillary longevity benefits.
For instance, over 50 years of observational data demonstrate lower mortality rates and reduced age-related disease among diabetes patients using metformin. From this observational data, we can take the next step to explore the mechanism behind such health outcomes. In the case of metformin, mTOR inhibition, and lower IGF-1 levels are of particular interest.
Observational research data has led researchers to study an unlikely candidate for longevity science: Low-Dose Naltrexone (LDN). Originally developed as a treatment for addiction, LDN's impact on our biological systems extends far beyond its intended purpose.
The interest surrounding LDN in longevity research is rooted in its ability to increase endogenous endorphins and the healthspan-promoting implications of this increase. Endorphins are natural hormones produced by our bodies known not only for their role in pain perception and pleasure but also in modulating the immune response.
When LDN is administered at lower doses, its active ingredient, Naltrexone, acts to subtly increase the production of endorphins, leading to a boost in overall well-being while also initiating a cascade of anti-inflammatory responses.
In this analysis of the latest research on LDN, we provide a comprehensive look at the current state of research on LDN, its proposed mechanisms of action, and the potential implications for its clinical application.
We will also explore how LDN functions in the treatment of three chronic inflammatory diseases: Multiple Sclerosis, Fibromyalgia, and Inflammatory Bowel Disease (IBD). Throughout this analysis, we will see recurring themes of the therapeutic benefits of LDN being driven by its inherent anti-inflammatory properties, combined with its subtle ability to enhance the production of endogenous opioids.
As we delve into the mechanisms by which LDN exerts its effects, it's crucial to appreciate the multi-layered complexity of human biochemistry. This complexity often means that a single molecule, like Naltrexone, can have multiple targets and functions within the body, leading to an array of effects.
Naltrexone is an opioid antagonist that blocks opioids from binding to their intended receptor. At the full dosage, it blocks opioid receptors to reduce the euphoria associated with opioids. By decoupling the euphoric benefits of opiates by blocking opioid receptors, Naltrexone, at full dosage, reduces dependency on opiates.
However, at lower dosages (as in LDN), the story becomes more intricate. At these low doses, LDN targets multiple pathways associated with healthspan. Its effects on longevity pathways and its ability to target some of the hallmarks of aging is our primary interest.
In order to understand the therapeutic advantages of LDN, it is crucial to understand how it elevates the levels of the opioid growth factor.
The opioid growth factor (OGF), also known as Met5-enkephalin, and its receptor, the opioid growth factor receptor (OGFr), play a crucial role in inhibiting cell proliferation and maintaining proper cell growth, which is important in the context of cancer and other chronic diseases caused by cellular dysfunction.
The OGF is an endogenous opioid, meaning it's naturally produced within the body. OGF interacts specifically with its corresponding receptor, the opioid growth factor receptor (OGFr), which is found in the nuclei of cells throughout the body.
The binding of OGF to OGFr initiates a cascade of intracellular events that typically inhibit cell proliferation. This natural braking mechanism helps to regulate the growth and development of cells and tissues, ensuring they don't multiply too quickly or excessively.
LDN is what we call an OGF antagonist. When LDN is introduced, it transiently blocks OGFr, disrupting the regular OGF-OGFr interaction. As a compensatory response to this blockage, the body increases the production of OGF, leading to a higher concentration of OGF peptides circulating in the body.
Once the effect of LDN diminishes due to its short half-life, the increased levels of OGF are now free to interact with OGFr. __The resulting enhanced OGF-OGFr activity can lead to an even more potent response in regulating dysfunctional cell proliferation and tissue repair than what would occur under normal physiological conditions. __
In addition to its obvious impacts on cancer, this reduction of cell proliferation has the potential to influence a variety of health and disease states, including autoimmune disorders, inflammation, pain management, and even cancer progression.
Chronic inflammation lies at the core of numerous debilitating diseases, from autoimmune disorders to neurodegenerative conditions. Inflammation is a complex biological response orchestrated by the immune system to combat harmful stimuli, such as pathogens or tissue damage.
While acute inflammation serves a protective purpose, chronic inflammation can be detrimental, leading to tissue damage and contributing to the progression of various diseases and the propagation of cellular senescence.
As we age, inflammation not only increases but accelerates the aging process. In fact, if you were to look at a tissue biopsy of an older person and compare it to a younger person, you could easily distinguish the two—the older person's biopsy would have much more inflammation.
Inflammatory cells, such as macrophages and lymphocytes, discharge signaling molecules known as cytokines, playing a pivotal role in sustaining an inflammatory response. Targeting these cells and cytokines has become a focal point for the development of effective anti-inflammatory therapies to treat chronic inflammation.
One fascinating aspect of LDN's mechanism of action involves its potential to reduce inflammation. Preclinical studies suggest that LDN modulates the activity of immune cells, such as macrophages and lymphocytes, leading to a reduction in their inflammatory response.
The surge in OGF levels, which we see with LDN administration, has a secondary impact on suppressing chronic inflammatory responses. OGF does this by influencing the production of cytokines.
Several different cell types coordinate their efforts as part of the immune system, including B cells, T cells, macrophages, mast cells, neutrophils, basophils, and eosinophils. Each of these cell types has a distinct role in the immune system and communicates with other immune cells using secreted cytokines.
In the presence of higher OGF levels, there is a decrease in the production of pro-inflammatory cytokines and, conversely, an increase in the production of anti-inflammatory cytokines. This alteration in the cytokine profile leads to a more balanced, less inflammatory immune response.
In a 2017 study led by Dr. Jarred Younger from the Neuro-inflammation, Pain, and Fatigue Laboratory, patients with Fibromyalgia were put on a 10-week administration of LDN. The study found that, after eight weeks of LDN administration, plasma levels of a range of broadly pro-inflammatory cytokines were decreased. In addition, we found that participants reported less pain and symptoms following LDN. These results support the hypothesis that LDN may help chronic pain conditions, such as Fibromyalgia, by acting as an atypical anti-inflammatory medication.
Another study from Dr. Prosenjit Mondal's lab showed that LDN delivered anti-inflammatory as a downstream consequence of increasing glucose tolerance and insulin sensitivity.
The study administered LDN to mice who were hyperinsulinemic due to a high-calorie diet. In the experiment, the mice treated with LDN were substantially more glucose tolerant than the control group and had reduced basal insulin levels suggesting that the LDN improved insulin sensitivity and enhanced glucose tolerance.
Hyperinsulinemia is closely linked to pro-inflammatory conditions that lead to insulin resistance. With the relationship between insulin and inflammation in mind, the research group then tested the possible involvement of hyperinsulinemia in inducing the release of pro-inflammatory cytokines.
Hyperinsulinemic mice showed a significantly enhanced release of pro-inflammatory mediators IL-1β, TNFα, and IL-6. The researchers found that LDN treatment reduced hyperinsulinemia-induced serum IL-1β, TNFα, and IL-6 levels.
This data suggest that 1) the diet-induced hyperinsulinemia that the mice were exposed to resulted in the increase of various pro-inflammatory molecules that are drivers of chronic inflammation, and 2) LDN treatment significantly reduced the pro-inflammatory markers in the serum samples that they studied by virtue of its ability to increase insulin sensitivity and glucose tolerance.
This research seems to indicate that reducing overall glucose levels and increasing insulin sensitivity, there is a downstream reduction of inflammatory markers. LDN's ability to decrease inflammatory molecules is at least partly affected by its ability to increase insulin sensitivity. By reducing absolute insulin levels and inflammation, LDN targets two very important hallmarks of aging.
LDN appears to diminish harmful inflammation by specifically targeting and blocking Toll-like receptor 4 (TLR4). Toll-like receptors are a family of proteins that serve as sentinels of the immune system, recognizing specific molecular patterns found in the outer membrane of certain bacteria.
TLR4 is found in various immune cells, such as macrophages and dendritic cells. When TLR4 recognizes specific pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), it triggers an inflammatory response and activates the immune system to combat infections and tissue damage.
When TLR4 binds to bacterial cell walls or other molecules on a pathogen, it triggers a signaling cascade that leads to the activation of pro-inflammatory transcription factors. This activation results in the production of pro-inflammatory cytokines (e.g., interleukin-1β, interleukin-6, tumor necrosis factor-alpha), chemokines, and other mediators of inflammation.
In chronic inflammatory conditions, TLR4 may be persistently activated due to repeated exposure to pathogens or persistent release of DAMPs from damaged tissues. This prolonged activation can lead to a continuous cycle of inflammation and tissue injury, contributing to the chronicity of the inflammatory response.
LDN blocks TLR4, thereby reducing the ensuing immune responses. By binding to TLR4, LDN potentially interferes with the downstream signaling pathways that trigger the production of pro-inflammatory cytokines. This blockade of TLR4 activation by LDN, therefore, reduces excessive inflammation and restoring immune balance.
The reduction of TLR4 activity by LDN is significant in autoimmune diseases where aberrant immune activation and inflammation are drivers of the disease state.
Neuronal atrophy and inflammation are associated with cognitive decline as we get older. One potential avenue to increase the survival and growth of neurons and the formation and stabilization of synaptic connections is to increase molecules called neurotrophic factors.
Neurotrophic factors are proteins crucial for neuronal development, synaptic plasticity, and effective neuronal communication, all needed for optimal brain health.
Decreased levels of neurotrophic factors are associated with neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease. Strategies to increase the production and activity of neurotrophic factors have become a focal point in neuroprotection research.
LDN delivers its neuroprotective benefits through its capability to stimulate the synthesis of neurotrophic factors, thereby supporting the growth and survival of nerve cells. The relationship between LDN and BDNF is particularly important to preserving cognitive function.
Emerging evidence suggests that LDN may offer a means of enhancing the production of neurotrophic factors, with a particular focus on the Brain-Derived Neurotrophic Factor (BDNF). BDNF is a specific type of neurotrophic factor, which is particularly important for brain plasticity, learning, memory, and overall cognitive function.
Preclinical studies show that LDN administration can increase BDNF levels within the brain. A study led by Dr. Mei-Chuan Ko, out of the University of Michigan Medical School, showed that increased endogenous opioids after LDN administration is associated with higher levels of BDNF mRNA.
By increasing BDNF production, LDN may facilitate the formation of new neuronal connections, promote neuronal survival, and enhance overall brain health. The capacity of LDN to enhance the production of neurotrophic factors, such as BDNF, holds promise for neurodegenerative diseases. Conditions like Alzheimer's disease, Parkinson's disease, and other age-related cognitive disorders involve progressive neuronal loss and synaptic degeneration.
LDN's neuroprotective benefits are not limited to BDNF. As we will discuss in the section discussing the role of inflammation in glial cells, additional neuroprotective benefits are derived from anti-inflammatory effects in neuronal cells.
Opioid receptors are distributed throughout the body, including the brain, spinal cord, and peripheral tissues. When activated by endogenous opioids, such as endorphins and enkephalins, these receptors contribute to pain inhibition.
Enkephalins are small peptide hormones, naturally produced by the body, that play important roles in pain reduction. Enkephalins, similar to endorphins, are produced within the body and act as neurotransmitters that bind to opioid receptors. They are primarily found in the central nervous system and are involved in regulating pain signals. Like endorphins, enkephalins bind to opioid receptors to reduce the perception of pain.
When LDN temporarily blocks opioid receptors, it not only prompts an increase in endorphin production but also stimulates the release of enkephalins like OGF.
The enhanced production of enkephalins, along with endorphins, contributes to the overall pain-relieving effects of LDN. The combined action of these endogenous opioids helps to dampen pain signals, alleviate discomfort, and promote a sense of well-being.
Beyond pain management, the endorphin boost induced by LDN may also have implications for mood regulation. Endorphins are known to contribute to feelings of well-being, euphoria, and relaxation. By enhancing endorphin production, LDN might offer a potential avenue for individuals dealing with mood disorders, such as depression or anxiety, to find relief and experience an improvement in their emotional well-being.
The relationship between LDN and glial cells is an important aspect of LDN's potential neuroprotective properties. We've previously discussed the anti-inflammatory benefits of LDN. This anti-inflammatory effect is important in the central nervous system. It is believed LDN operates as a novel anti-inflammatory agent in the central nervous system via its effects on glial cells.
Glial cells, often referred to as the "supporting cells" of the nervous system, play a crucial role in maintaining the health and function of neurons. However, in certain circumstances, these cells can become overactivated and contribute to the development and persistence of pathological pain states. This phenomenon is particularly relevant in chronic pain conditions, where glial cell activation can exacerbate pain signals and promote inflammation.
Of particular interest is the impact LDN has on microglial cells. Microglia act as the first line of defense in the CNS against infections, injuries, and foreign substances. When there is damage or inflammation in the brain, microglia become activated and migrate to the site of injury or infection. They can phagocytose (engulf and remove) damaged cells, debris, and foreign invaders, helping clear the area and initiate healing.
Microglia, as central nervous system immune cells, can be activated by various triggers. Once activated, they release inflammatory and excitatory factors that may cause a range of symptoms and medical conditions, including pain sensitivity, fatigue, cognitive disruption, sleep disorders, mood disorders, and general malaise. In cases of chronic activation, the ensuing pro-inflammatory cascade can become neurotoxic, leading to several harmful effects.
One proposed mechanism of how LDN modulates glial cells involves the interaction between LDN and TLR4. As we discussed earlier, LDN is thought to act as an antagonist to TLR4, effectively blocking its activity and disrupting its inflammatory cytokine response. By blocking TLR4 activity, LDN may inhibit the activation of microglial cells, stopping the ensuing pathological pain states.
Conditions such as Fibromyalgia may involve chronic glial cell activation and the subsequent production of pro-inflammatory factors. The hypothesis connecting LDN's anti-inflammatory effects to its impact on microglia activation is indirectly supported by the considerable symptomatic overlap between Fibromyalgia and cytokine-induced sickness behaviors.
How can we discern whether the positive response in Fibromyalgia is due to the increase in endogenous opioids or if it is due to the anti-inflammatory effects?
The hypothesis suggesting that LDN operates through glial cells to exert its beneficial actions is supported by Dr. Younger's work with dextro-naltrexone. Dextro-naltrexone is an isomer of Naltrexone. It is active at microglia receptors but lacks activity on opioid receptors.
Despite this distinction, dextro-naltrexone still possesses pain prevention and neuroprotective properties, indicating that the pain prevention, anti-inflammatory, and neuroprotective effects of Naltrexone do not rely on opioid receptors but are delivered through its anti-inflammatory benefits on microglia.
By targeting glial cells and modulating their activity, LDN is a potential therapeutic strategy for certain chronic pain conditions. Reducing glial cell activation and the subsequent dampening of the pro-inflammatory response within the nervous system contributes to restoring a more balanced inflammation state. This restoration, in turn, has the potential to decrease pain sensitivity and improve overall pain management for individuals experiencing chronic pain.
LDN's mechanisms of action are important to understanding how LDN can be utilized to treat serious medical conditions. Several studies have explored LDN's effectiveness in managing various chronic disease states.
The investigation of LDN as a potential treatment for multiple sclerosis (MS) began in 2005. A notable early study conducted in multiple centers explored the safety and tolerability of LDN in patients with primary progressive MS. The study also observed a significant decrease in spasticity, a common symptom experienced by individuals with MS.
What is the mechanism of action?
The study provided insights into the potential mechanism of action underlying LDN's effects in MS. The researchers measured the levels of β-endorphins, which are naturally occurring opioids, in the peripheral blood mononuclear cells of patients. They found that the administration of LDN coincided with an increase in β-endorphin levels, which is consistent with what we know about LDN's global mechanism of action.
These findings reinforce the hypothesis that LDN affects MS by targeting specific opioid receptors, which are also implicated in neuroinflammatory processes. In doing so, LDN may help regulate immune responses and reduce inflammation in the central nervous system, a key component of MS pathology.
To further understand the potential of LDN as a treatment for multiple sclerosis (MS), experimental studies have been conducted using a mouse model of the disease known as autoimmune encephalomyelitis.
One notable finding from these experimental studies is that LDN therapy restored reduced levels of OGF. This is significant because OGF signaling is an area of interest in the pathophysiology of MS. The reduction in OGF levels observed before the onset of clinical symptoms in the mice was reversed upon LDN treatment, suggesting a potential therapeutic role for LDN in restoring this imbalance of endogenous opioids.
In addition to its effects on OGF, in vitro experiments have also shed light on LDN's potential impact on immune cells involved in autoimmune responses. These studies have indicated that LDN may suppress the proliferation of B and T cells, which play crucial roles in the autoimmune processes underlying MS. This suggests that LDN may have immunomodulatory effects that can help regulate the aberrant immune response seen in MS.
Fibromyalgia is a complex health condition. It's known for causing widespread pain throughout the body, extreme tiredness, and problems with thinking clearly. Despite significant research, we're still not entirely sure what causes it. Scientists have three main theories they're currently investigating.
The first theory suggests that there may be a problem with how the brain and spinal cord communicate with each other, leading to increased pain sensitivity. For example, a person with Fibromyalgia might feel pain from something that wouldn't normally hurt (a condition known as allodynia), or they may feel more pain than expected during repeated exposure to a painful stimulus.
Researchers think this might be because of changes in how the body's natural opioid function, alterations in how the body responds to pain relief medications and changes in the immune system.
The second theory is related to the body's automatic control system, known as the autonomic nervous system. This system controls things like your heart rate and digestion without you having to think about it. Some scientists believe that Fibromyalgia might be linked to this system not working correctly, possibly due to ongoing stress. It is believed that this could lead to the body's 'fight or flight' response being constantly activated, resulting in changes in the body's pain-sensing system.
The third theory revolves around inflammation in the nerves located outside the brain and spinal cord. People with Fibromyalgia often have higher levels of certain substances that cause inflammation and enhance pain sensation. This suggests that inflammation might add to the pain felt in the brain and spinal cord and the nerves throughout the rest of the body.
Fibromyalgia has been the subject of several studies exploring the potential benefits of LDN. As discussed earlier, LDN can interfere with the activity of Toll-like receptor 4 in glial cells. This is important because Toll-like receptor 4 plays a role in triggering inflammation and pain signaling. __By interfering with TLR4 activity, particularly in microglial cells, LDN can reduce the activation of inflammation and pain systems, particularly brain inflammation. __
From a patient outcome perspective, LDN there are a number of data points that suggest that LDN has positive effects on Fibromyalgia outcomes.
In a pilot study on LDN and Fibromyalgia conducted by Dr. Younger, a group of ten women with Fibromyalgia participated in a single-blind placebo-crossover pilot trial. The study consisted of a two-week placebo period followed by eight weeks of daily administration of 4.5 mg LDN.
The results showed that six patients experienced a significant reduction in symptoms, surpassing the 30% threshold. Overall, there was a notable reduction of 2.3% in symptoms during the placebo phase, compared to a substantial reduction of 32.5% during the LDN phase relative to the baseline.
Additional benefits included reductions in daily pain, peak pain, fatigue, and stress levels. The study also identified a higher initial erythrocyte sedimentation rate—a measure of inflammation in the body—as a predictor for a positive response to LDN, indicating the potential of LDN in targeting the inflammatory component of Fibromyalgia. The study showed that if patients had higher inflammatory markers, they were more likely to have a positive response to the LDN treatment.
Building on these findings, Dr. Younger's lab conducted a 20-week randomized, placebo-controlled, double-blind crossover study involving 28 patients. The study comprised 12 weeks of LDN treatment and four weeks of placebo. Results showed that 57% of patients met the criteria for a positive response to LDN, demonstrating its efficacy in symptom reduction.
In a more recent study conducted by Dr. Younger, the effects of LDN treatment on cytokine levels were investigated in a group of eight women with Fibromyalgia. Cytokines are signaling molecules involved in the immune response and inflammation. The study, spanning a 10-week period, aimed to understand how LDN affects the levels of various inflammatory cytokines.
The results of the study revealed a significant decrease in the levels of several inflammatory cytokines following LDN treatment. These included IL-6, TNF-α, transforming growth factor (TGF)-β, IL-17, IL-1, IL-2, and interferon-α. The reduction in these cytokines suggests and reinforces that LDN possesses anti-inflammatory properties, which could be a key factor in its beneficial impact on fibromyalgia symptoms.
By reducing the levels of pro-inflammatory cytokines, LDN may help alleviate inflammation, leading to a reduction in symptoms and an improvement in overall well-being in patients with Fibromyalgia.
Crohn's disease (CD) is a chronic inflammatory condition that can affect any part of the gastrointestinal tract. Its symptoms can be debilitating and may include abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
It's a disease that is typically characterized by periods of intense flare-ups followed by periods of remission. Achieving and maintaining this remission is a key goal of treatment, as it can help prevent further complications, such as the development of fistulas or strictures, and improve patients' quality of life.
Over the past decade, there has been a significant expansion of the therapeutic landscape for Crohn's Disease. Many of these newer treatments have different mechanisms of action, meaning they work in different ways to reduce inflammation and promote remission. However, while these treatments can be effective, they are not without potential drawbacks.
Immunosuppressive drugs and biological therapies, which target specific parts of the immune system to control inflammation, are commonly used treatments for Crohn's Disease. However, they can have serious side effects.
Beyond the safety concerns, there is also the issue of cost. Biological therapies, in particular, can be extremely expensive, which raises concerns about their long-term sustainability, especially given the chronic nature of CD. This has led to increased interest in finding alternative treatments that are not only effective and safe but also more affordable.
The discussion of CD treatment is further complicated by the fact that CD is a progressive disease, and over time, patients may find that treatments that were once effective no longer work as well. This phenomenon, known as treatment cycling, leaves patients with fewer and fewer approved options.
In this context, the pursuit of alternative treatments for CD is crucial. The ideal treatment would be cost-effective, have minimal side effects, and have a different mechanism of action to provide an option for patients who have not responded to or cannot tolerate existing treatments. Researchers have been intrigued by the potential of LDN as a treatment option for Chron's disease and other inflammatory bowel diseases.
As we've illustrated, the role of the opioid system in the body's physiological processes extends beyond its well-known function in pain management. Among these less-understood roles is its potential involvement in gastrointestinal inflammation, a key characteristic of inflammatory bowel diseases (IBD) such as Crohn's disease.
Endogenous opioids seem to play a part in the process of inflammation. The μ-opioid receptor (MOR), one of the three types of opioid receptors in the body, is upregulated, or more abundant, in individuals with IBD. This suggests that the MOR may be involved in the disease's mechanism, possibly by regulating pro-inflammatory cytokines (proteins that mediate and control immune and inflammatory responses) and T-cell proliferation.
The enhanced presence of MOR in IBD sufferers has led to the exploration of selective MOR agonists—compounds that can bind to and activate these receptors—as a potential novel treatment approach for IBD.
This is where Naltrexone comes into play. Naltrexone is known to act as an antagonist for the MOR. This means it binds to the MOR but, instead of activating it, blocks it from being activated by other substances.
Instead of blocking the MOR, low-dose Naltrexone increases the levels of endogenous encephalin and endorphin (types of endogenous opioids) and positively modulates the MOR, leading to reduced gut inflammation.
Experimental models are often used in research to understand the complex disease mechanisms and to test potential therapeutic strategies before they are deemed safe and effective for human trials. In this context, researchers used mouse and rat models to study inflammatory bowel disease (IBD) and the effects of LDN. They found that in these animal models, LDN reduced inflammation partly by reducing the production of pro-inflammatory cytokines.
The research group explored the role of endoplasmic reticulum (ER) stress in IBD. The endoplasmic reticulum is a part of the cell responsible for protein folding, transport, and lipid metabolism. When the ER is not functioning correctly, it can lead to a condition called ER stress, which can cause inflammation and cell death.
Firstly, they chemically induced ER stress in two kinds of intestinal cells and found that Naltrexone was able to decrease the levels of a protein that typically increases in response to ER stress. They then induced ER stress by introducing bacteria to the cells and discovered that Naltrexone significantly reduced the bacteria-induced increase of this protein.
To confirm these findings, the team also created organoids—miniaturized and simplified versions of an organ produced in vitro in three dimensions—from biopsies of two IBD patients and observed a similar decrease in the expression of the ER stress-related protein when treated with Naltrexone.
Finally, they studied tissue samples from patients treated with low-dose Naltrexone and found that ER stress levels decreased with the treatment, although statistical significance wasn't reached due to the small sample size.
Overall, these experiments suggest that Naltrexone may help reduce ER stress in intestinal cells, which could potentially explain its positive effects on IBD treatment.
In our analysis of the most recent research data concerning Low Dose Naltrexone (LDN), it becomes increasingly evident that LDN's therapeutic benefits are multifaceted and complex. Consistently, across a broad spectrum of pathologies where LDN has potential applications, it exhibits a consistent ability to modulate chronic inflammation, particularly within the nervous system.
Moreover, LDN's role in enhancing the production of endogenous opioids adds another dimension to its therapeutic impact. This has significant implications for treating chronic inflammatory conditions, but its potential benefits extend further. By acting on such fundamental physiological processes, LDN could also contribute to improving overall healthspan.
Although the full mechanisms of LDN remain to be fully elucidated, the evidence to date suggests it could represent a promising approach to treating chronic inflammation and enhancing healthspan. The breadth and depth of LDN's potential application underscore the need for continued research into this intriguing compound.
Choubey, A., Girdhar, K., Kar, A. K., Kushwaha, S., Yadav, M. K., Ghosh, D., & Mondal, P. (2020). Low-dose naltrexone rescues inflammation and insulin resistance associated with hyperinsulinemia. Journal of Biological Chemistry. Elsevier.
Zhang H, Torregrossa MM, Jutkiewicz EM, Shi YG, Rice KC, Woods JH, Watson SJ, Ko MC. Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects. Eur J Neurosci. 2006 Feb;23(4):984-94. doi: 10.1111/j.1460-9568.2006.04621.x. PMID: 16519663; PMCID: PMC1462954.
Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. PMID: 24526250; PMCID: PMC3962576.
Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther. 2000 May;293(2):607-17. PMID: 10773035.
Valentino RJ, Katz JL, Medzihradsky F, Woods JH. Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci. 1983;32(25):2887–2896. doi: 10.1016/0024-3205(83)90325-9.
Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, Huang Y, Rice KC, Watkins LR. (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain. 2012;13(5):498–506. doi: 10.1016/j.jpain.2012.02.005.
Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics 2012;53(6):591–94. doi: 10.1016/j.psym.2011.11.006.
Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009 May-Jun;10(4):663-72. doi: 10.1111/j.1526-4637.2009.00613.x. Epub 2009 Apr 22. PMID: 19453963; PMCID: PMC2891387.
Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007 Apr;102(4):820-8. doi: 10.1111/j.1572-0241.2007.01045.x. Epub 2007 Jan 11. PMID: 17222320.
Lie, M.R.K.L., van der Giessen, J., Fuhler, G.M. et al. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 16, 55 (2018). https://doi.org/10.1186/s12967-018-1427-5
Sign up for The Longevity Blueprint, a weekly newsletter from Healthspan analyzing the latest longevity research.